Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer
Open Access
- 5 September 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-8
Abstract
Breast cancer is the most common malignancy in women, and neoadjuvant chemotherapy has been recommended to the patients with locally advanced breast cancer as the initial treatments. Long non-coding RNA (lncRNA) MEG3, an identified tumor suppressor, has been implicated in the development of various cancers. However, there is no data to evaluate the effect of MEG3 polymorphisms on neoadjuvant treatment in the breast cancer. Genotyping was performed using Nanodispenser Spectro CHIP chip spotting and Mass ARRAY Compact System. Univariate and multivariate logistic regression analyses were used to analyze the associations between the MEG3 polymorphisms and the pathological complete response (pCR). The disease-free survival (DFS) was estimated by the Kaplan-Meier method, and multivariate Cox proportional hazards models were used to calculate the hazard ratios (HRs) with a 95% confidential interval (CI). A total of 144 patients with available pretreatment blood species were enrolled in the SHPD002 clinic trial of neoadjuvant chemotherapy for breast cancer. MEG3 rs10132552 were significantly associated with good response (Adjusted OR = 2.79, 95% CI 1.096–7.103, p = 0.031) in dominant model. Median follow-up time was 20 months. In multiple regression analysis, rs10132552 TC + CC (adjusted HR = 0.127, 95% CI 0.22–0.728, p = 0.02) and rs941576 AG + GG (adjusted HR = 0.183, 95% CI 0.041–0.807, p = 0.025) were significantly associated with good DFS. MEG3 rs7158663 (OR = 0.377, 95% CI 0.155–0.917, p = 0.032) were associated with a low risk of hemoglobin decrease in dominant models. LncRNA MEG3 polymorphisms were associated with the chemotherapy response and toxicity of paclitaxel and cisplatin. The result indicates that MEG3 polymorphisms can be considered as the predictive and prognostic markers for the breast cancer patients. Retrospectively registered (ClinicalTrials. Gov identifier: NCT02221999 ); date of registration: Aug 20th, 2014.Keywords
Funding Information
- Multidisciplinary Cross Research Foundation of Shanghai Jiaotong University (YG2017QN49, ZH2018QNA42)
- Clinical Research Plan of SHDC (16CR3065B)
- Nurturing Fund of Renji Hospital (pyzy16-018)
- Science and Technology Commission of Shanghai Municipality (15JC1402700)
- Foundation of Shanghai Municipal Commission of Health and Family Planning (201640006)
- National Natural Science Foundation of China (81172505)
This publication has 30 references indexed in Scilit:
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Annals of Oncology, 2015
- Genetic link of type 1 diabetes susceptibility loci with rheumatoid arthritis in Pakistani patientsImmunogenetics, 2015
- The role and interaction of imprinted genes in human fetal growthPhilosophical Transactions of the Royal Society B: Biological Sciences, 2015
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialThe Lancet Oncology, 2014
- MEG3 noncoding RNA: a tumor suppressorJournal of Molecular Endocrinology, 2012
- The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetesNature Genetics, 2009
- A simple system for grading the response of breast cancer to neoadjuvant chemotherapyAnnals of Oncology, 2009
- Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapyAnnals of Oncology, 2007
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 2005
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2003